OneCellDx and Genetics Institute of America Partner to Launch OncoPredikt HRD Assay

OneCellDx and Genetics Institute of America Partner to Launch OncoPredikt HRD Assay

May 31, 2022 by Business Wire Health News

Key Facts

  • May 31, 2022 02:45 PM Eastern Daylight Time CUPERTINO, CA & DELRAY BEACH, Fla.--(BUSINESS WIRE)--OneCellDx and Genetics Institute of America announced today that they have signed a memorandum of understanding for a diagnostics commercialization agreement for the OneCellDx OncoPredikt HRD Assay.
  • Genetics Institute of America will run a validation study in its CAP Accredited, CLIA certified facility and launch the laboratory developed test upon successful completion and acceptance of the study.
  • “Our team of scientists and engineers have developed a uniquely impactful solution and are very excited to partner with the team at Genetics Institute of America in bringing OncoPredikt HRD to market,” said Mohan Uttarwar, Co-founder and CEO of OneCellDx.
  • Bringing the OncoPredikt HRD test to market will help in accelerating the development of novel pharmaceuticals, improving the care of thousands of patients,” said Holly Magliochetti, CEO and Founder of Genetics Institute of America.

Click To Read Full Article

EVENT
GEOGRAPHY
PERSON
MISCELLANEOUS

This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.

Was this content valuable for you?